表紙
市場調查報告書

眼科藥的全球市場 - 成長,趨勢,預測(2019年∼2024年)

Ophthalmic Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 661011
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
Back to Top
眼科藥的全球市場 - 成長,趨勢,預測(2019年∼2024年) Ophthalmic Drugs Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年03月01日內容資訊: 英文 114 Pages
簡介

眼科藥的全球市場的成長,由於眼科疾病的罹患率及盛行率的上升,藥物研發的研究開發活動增加,對聯合治療開發的關注高漲等而受促進。

本報告提供眼科藥的世界市場調查,市場概要,各醫藥品類型、產品類型、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 眼科疾病的罹患率、盛行率的上升
    • 藥物研發的研究開發活動的增加
    • 對聯合治療的開發的關注高漲
  • 市場阻礙因素
    • 受歡迎醫藥品的專利到期
    • 發展中國家的健康保險的缺乏
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 各醫藥品類型
    • 青光眼治療藥
    • 乾眼症藥
    • 眼科用抗過敏/抗發炎藥
    • 視網膜藥
    • 抗感染疾病藥
    • 其他
  • 各產品類型
    • 一般用醫藥品
    • 醫療用醫藥品
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Aerie Pharmaceuticals Inc.
    • Allergan
    • Bausch Health Companies Inc.
    • Bayer AG
    • F. Hoffmann-La Roche Ltd
    • Hoya Corporation
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • 參天製藥

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 46723

Market Overview

The major factors attributed to the growth of the ophthalmic drugs market include the increasing incidence and prevalence of eye-related disorders, rising R&D activities pertaining to the development of novel drugs, and increasing focus on developing combination therapies.

The increasing prevalence of eye diseases is increasing the demand for ophthalmic drugs, globally. In many developed and developing countries, eye conditions have emerged as potential threats to the status of sight of their populations. The increase in the prevalence of diabetes in various countries has caused diabetic retinopathy to be added to the priority list. Glaucoma, an eye disease known for centuries, remains on the public health agenda due to difficulties in its early diagnosis and frequent necessity of life-long treatment. According to the WHO, in 2018, it was estimated that approximately 1.3 billion people were living with some form of vision impairment, 188.5 million people had a mild vision impairment, 217 million had moderate to severe vision impairment, and 36 million people are blind. Globally, the leading causes of vision impairment are uncorrected refractive errors and cataracts, and the majority of people with vision impairment are over the age of 50 years. According to the WHO, chronic eye diseases are the number one cause of vision loss, with the top two causes being unoperated cataracts and uncorrected refractive errors. The former is the leading cause in countries with low- or middle-incomes. More than 80% of the vision impairments are curable or preventable, which means that these drugs are required for the management of the diseases. Hence, the rising incidence of eye-related disorders is projecting a great impact on the growth of market studied.

Scope of the Report

As per the scope of the report, ophthalmic drugs are the drugs used for treating glaucoma, cataracts, diabetic retinopathy, and other ophthalmic disorders. An increasing prevalence of eye disorders and increasing R&D on the development of novel drugs are the major factors driving growth in the global ophthalmic drugs market. The market is segmented by drug class, product type, and geography.

Key Market Trends

The Dry Eye Segment under Drug Class is Expected to Account for the Largest Market Share during the Forecast Period

Dry eye disease (DED) is a multi-factorial disease of the tear film and ocular surface that results in ocular discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is a generally under-diagnosed clinical condition, as patients often attribute the experienced DED symptoms to aging, and hence, it remains an under-researched condition in the low- and middle-income countries. The prevalence of DED can be as high as 30% of the total population. In the last decade, only one drug was approved for the treatment of DED by the US Food and Drug Administration (FDA) (i.e., Restasis by Allergan Inc.). DED is a major public health problem, the burden of which is likely to increase due to the increasing proportion of the aging population and the adoption of modern lifestyle. Dry eye disease is a common ocular disorder in the elderly and a frequent cause of eye care visits among this age group. The total annual cost of dry eye drug to the US economy can be more than USD 55 billion. Thus, the development of new drug treatments for dry eye is essential for both the dry eye patients and the ophthalmic industry. Many drugs are in the pipeline for dry eye diseases. The increasing prevalence of DED, approval of drugs for its treatment, and government initiatives to eradicate it are the main factors spurring the growth of the market studied.

The Asia-Pacific Segment is Expected to Account for the Fastest Growth Rate

The ophthalmic drugs market is expanding and growing, globally. The market has been witnessing an especially exponential growth in the Asia-Pacific region. Glaucoma and tear substitute (for dry eye) drugs are the leading products in Asia-Pacific. India is likely to be among the top three pharmaceutical markets by incremental growth and the sixth-largest market, globally, in absolute size, according to the Clinical and Experimental Vision and Eye Research, India, 2018. Increase in the number of middle-class households, advancement in medical infrastructure, and the increasing penetration of health insurance in the country are likely to play a significant role in influencing this growth. According to the National Health Policy (NHP), in India, glaucoma is the leading cause of irreversible blindness with at least 12 million people have affected and nearly 1.2 million people having blinded from the disease. More than 90% of the cases of glaucoma remain undiagnosed in the country.

Moreover, the prevalence of glaucoma increases with age. Thus, the rising prevalence of glaucoma and an increase in healthcare expenditure are spurring the growth of the ophthalmic drugs market in India. Furthermore, the country's government is also playing an important role, since the cost of glaucoma treatment in India is one of the lowest in the world.

Competitive Landscape

The market studied is composed of a combination of both small and large firms. Most of the big companies are focusing on research and development to bring innovative products to the market. Some of the major players in the ophthalmic drugs market are Aerie Pharmaceuticals Inc., Allergan, Bausch Health, Bayer AG, F. Hoffmann-La Roche Ltd, Hoya Corporation, Novartis AG, Pfizer Inc., and Regeneron Pharmaceuticals Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence and Prevalence of Eye-related Disorders
    • 4.2.2 Rising R&D Pertaining to the Development of Novel Drugs
    • 4.2.3 Increasing Focus on Developing Combination Therapies
  • 4.3 Market Restraints
    • 4.3.1 Loss of Patent Protection for Popular Drugs
    • 4.3.2 Lack of Health Insurance in the Developing Countries
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Anti-glaucoma Drug
    • 5.1.2 Dry eye Drug
    • 5.1.3 Ophthalmic Anti-allergy/Inflammatory
    • 5.1.4 Retinal Drug
    • 5.1.5 Anti-infective Drugs
    • 5.1.6 Other Drugs
  • 5.2 By Product Type
    • 5.2.1 OTC Drug
    • 5.2.2 Prescription Drug
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Aerie Pharmaceuticals Inc.
    • 6.1.2 Allergan
    • 6.1.3 Bausch Health Companies Inc.
    • 6.1.4 Bayer AG
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Hoya Corporation
    • 6.1.7 Novartis AG
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Regeneron Pharmaceuticals Inc.
    • 6.1.10 Santen Pharmaceutical Co. Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top